Trust Company of Vermont’s ARK Genomic Revolution ETF ARKG Stock Holding History

Trust Company of Vermont’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13	Closed	-$306	–	1037
2024 Q4	$306	Buy	+13	New	+$320	﹤0.01%	1017
2023 Q1	–	Sell	-34	Closed	-$960	–	873
2022 Q4	$960	Buy	+34	New	+$1.08K	﹤0.01%	823
2022 Q1	–	Sell	-221	Closed	-$14K	–	335
2021 Q4	$14K	Buy	+221	New	+$15.3K	﹤0.01%	624
2021 Q3	–	Sell	-141	Closed	-$13K	–	326
2021 Q2	$13K	Hold	141	–	–	﹤0.01%	612
2021 Q1	$13K	Hold	141	–	–	﹤0.01%	603
2020 Q4	$13K	Buy	141 +41	+41%	+$3.27K	﹤0.01%	594
2020 Q3	$6K	Buy	+100	New	+$5.86K	﹤0.01%	650

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Trust Company of Vermont's ARKG Position: Q1 2025 in Review

Trust Company of Vermont sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2025, closing a stake of 13 shares — an estimated $306 sold.

Trust Company of Vermont first reported a position in ARKG in Q3 2020 and held it in 7 quarters. The position peaked at $14K in Q4 2021. 215 funds tracked by Wall St. Rank hold ARKG as of Q1 2025.

Trust Company of Vermont reported no remaining ARK Genomic Revolution ETF position as of Q1 2025 after selling out during the quarter.
Trust Company of Vermont sold 13 ARK Genomic Revolution ETF shares in Q1 2025, an estimated $306.
Trust Company of Vermont first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 7 quarters.
Trust Company of Vermont's ARK Genomic Revolution ETF position peaked at $14K in Q4 2021.
215 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2025.

Based on Trust Company of Vermont's 13F filing for Q1 2025, filed 24 Apr 2025.